Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 19, 2025

MDA-5 (D74E4) Rabbit mAb

RRID:AB_10694490
Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 5321, RRID:AB_10694490)

Antibody Information

URL: http://antibodyregistry.org/AB_10694490

Proper Citation: (Cell Signaling Technology Cat# 5321, RRID:AB_10694490)

Target Antigen: MDA-5

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: W, IP

Antibody Name: MDA-5 (D74E4) Rabbit mAb

Description: This recombinant monoclonal targets MDA-5

Target Organism: mouse, human

Clone ID: D74E4

Antibody ID: AB_10694490

Vendor: Cell Signaling Technology

Catalog Number: 5321

Alternative Catalog Numbers: 5321S

Record Creation Time: 20231110T070213+0000

Record Last Update: 20241115T001843+0000

Ratings and Alerts

No rating or validation information has been found for MDA-5 (D74E4) Rabbit mAb.

No alerts have been found for MDA-5 (D74E4) Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Zou T, et al. (2024) XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells. Cell reports, 43(2), 113600.

Cottrell KA, et al. (2024) Induction of Viral Mimicry Upon Loss of DHX9 and ADAR1 in Breast Cancer Cells. Cancer research communications, 4(4), 986.

Liu X, et al. (2024) The deubiquitinase BAP1 and E3 ligase UBE3C sequentially target IRF3 to activate and resolve the antiviral innate immune response. Cell reports, 43(8), 114608.

Jiao M, et al. (2024) VHL loss enhances antitumor immunity by activating the anti-viral DNA-sensing pathway. iScience, 27(7), 110285.

Zhuang Q, et al. (2024) RNA Methyltransferase FTSJ3 Regulates the Type I Interferon Pathway to Promote Hepatocellular Carcinoma Immune Evasion. Cancer research, 84(3), 405.

van Gemert F, et al. (2024) ADARp150 counteracts whole genome duplication. Nucleic acids research, 52(17), 10370.

Sinigaglia K, et al. (2024) An ADAR1 dsRBD3-PKR kinase domain interaction on dsRNA inhibits PKR activation. Cell reports, 43(8), 114618.

Jiao M, et al. (2024) Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma. Cancer research, 84(21), 3640.

Thierry S, et al. (2023) TL-532, a novel specific Toll-like receptor 3 agonist rationally designed for targeting cancers: discovery process and biological characterization. Microbial cell (Graz, Austria), 10(6), 117.

Arai Y, et al. (2023) Stimulation of interferon-? responses by aberrant SARS-CoV-2 small

viral RNAs acting as retinoic acid-inducible gene-I agonists. iScience, 26(1), 105742.

Kuang M, et al. (2023) XAF1 promotes anti-RNA virus immune responses by regulating chromatin accessibility. Science advances, 9(33), eadg5211.

Kong X, et al. (2023) Type I interferon/STAT1 signaling regulates UBE2M-mediated antiviral innate immunity in a negative feedback manner. Cell reports, 42(1), 112002.

Zhang W, et al. (2023) HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation. Cell reports, 42(11), 113352.

Jiang J, et al. (2022) LncNSPL facilitates influenza A viral immune escape by restricting TRIM25-mediated K63-linked RIG-I ubiquitination. iScience, 25(7), 104607.

Yang L, et al. (2022) Histone deacetylase 3 contributes to the antiviral innate immunity of macrophages by interacting with FOXK1 to regulate STAT1/2 transcription. Cell reports, 38(4), 110302.

Maharana S, et al. (2022) SAMHD1 controls innate immunity by regulating condensation of immunogenic self RNA. Molecular cell, 82(19), 3712.

Srour N, et al. (2022) PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade. Cell reports, 38(13), 110582.

Pan D, et al. (2022) SETDB1 Restrains Endogenous Retrovirus Expression and Antitumor Immunity during Radiotherapy. Cancer research, 82(15), 2748.

Li Y, et al. (2022) Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. Molecular cell, 82(20), 3901.

Berton S, et al. (2022) A selective PPM1A inhibitor activates autophagy to restrict the survival of Mycobacterium tuberculosis. Cell chemical biology, 29(7), 1126.